Just a moment, the page is loading...
Browse ALL STUDIES
Keyword Search
View All Selected
Clear All
Login / Create Account
Login
Create Account
Home
About Us
Privacy Policy
Minimum System Requirements
How To Join
Mission
Data Sponsors
Researchers
How It Works
How to Request Data
Review of Requests
Data Sharing Agreement
Access to Data
Independent Review Panel
Metrics
FAQs
News
Help/Contact Us
Development of a limited sampling strategy for pharmacokinetic studies with pemetrexed.
Proposal
5506
Title of Proposed Research
Development of a limited sampling strategy for pharmacokinetic studies with pemetrexed.
Lead Researcher
Rob ter Heine
Affiliation
Radboud University Medical Center
Funding Source
Potential Conflicts of Interest
Data Sharing Agreement Date
25 September 2018
Lay Summary
Pemetrexed is an important first line anticancer drug for treatment of non-small cell lung cancer and mesothelioma. We aim to perform minimally invasive pharmacokinetic studies with pemetrexed. To allow for a minimal invasive sampling strategy, we aim to develop a limited sampling strategy (LSS). Rich pharmacokinetic data, as obtained during drug development, is needed for the external validation of an LSS. For this purpose, we are requesting the clinical pharmacokinetic data of pemetrexed.
Study Data Provided
[{ "PostingID": 3864, "Title": "LILLY-H3E-MC-JMAS", "Description": "A Phase 1 Trial of ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer" },{ "PostingID": 3865, "Title": "LILLY-H3E-MC-JMAW", "Description": "A Phase 1 Pharmacokinetic Trial of LY231514 Administered Intravenously Every 3 Weeks in Advanced Cancer Patients with Varying Degrees of Renal Function" }]
Statistical Analysis Plan
Publication Citation
© 2024 ideaPoint. All Rights Reserved.
Powered by ideaPoint.
Help
Privacy Policy
Cookie Policy
Help and Resources